Kochat Veena, Kanjirakkuzhiyil Sumod, Baligar Prakash, Nagarajan Perumal, Mukhopadhyay Asok
Stem Cell Biology Laboratory, National Institute of Immunology, Aruna Asaf Ali Marg, New Delhi, 110067, India.
Experimental Animal Facility, National Institute of Immunology, New Delhi, India.
Stem Cell Res Ther. 2015 Jul 8;6(1):129. doi: 10.1186/s13287-015-0119-9.
Cell replacement therapy may be considered as an alternate approach to provide therapeutic dose of plasma factor VIII (FVIII) in patients with hemophilia A (HA). However, immune rejection limits the use of allogeneic cells in this mode of therapy. Here, we have examined the role of donor major histocompatibility complex (MHC)-stimulated host CD4(+)CD25(+) regulatory T (Treg) cells in suppressing immune responses against allogeneic uncommitted (Lin(-)) bone marrow cells (BMCs) for correction of bleeding disorder in HA mice.
Allogeneic donor Lin(-) BMCs were co-transplanted with allo-antigen sensitized Treg cells in HA mice having acetaminophen-induced acute liver injury. Plasma FVIII activity was determined by in vitro functional assay, and correction of bleeding phenotype was assessed on the basis of capillary blood clotting time and tail-clip challenge. The immunosuppression potential of the sensitized Treg cells on CD4(+) T cells was studied both in vitro and in vivo. Suppression of inflammatory reactions in the liver against the homed donor cells by sensitized Treg cells was analysed by histopathological scoring. Allo-specificity of sensitized Treg cells and long-term retention of immunosuppression were examined against a third-party donor and by secondary challenge of allogeneic donor cells, respectively. The engraftment and phenotype change of donor BMCs in the liver and their role in synthesis of FVIII and liver regeneration were also determined.
Co-transplantation of allogeneic Lin(-) BMCs with sensitized Treg cells led to systemic immune modulation and suppression of inflammatory reactions in the liver, allowing better engraftment of allogeneic cells in the liver. Allo-antigen priming led to allo-specific immune suppression even after 1 year of transplantation. Donor-derived endothelial cells expressed FVIII in HA mice, leading to the correction of bleeding phenotype. Donor-derived hepatocyte-like cells, which constitute the major fraction of engrafted cells, supported regeneration of the liver after acute injury.
A highly proficient FVIII secreting core system can be created in regenerating liver by transplanting allogeneic Lin(-) BMCs in HA mice where transplantation tolerance against donor antigens can be induced by in vitro allo-antigen primed Treg cells. This strategy can be beneficial in treatment of genetic liver disorders for achieving prophylactic levels of the missing proteins.
细胞替代疗法可被视为在甲型血友病(HA)患者中提供治疗剂量血浆凝血因子 VIII(FVIII)的另一种方法。然而,免疫排斥限制了这种治疗模式中同种异体细胞的使用。在此,我们研究了供体主要组织相容性复合体(MHC)刺激的宿主 CD4(+)CD25(+)调节性 T(Treg)细胞在抑制针对同种异基因未定向(Lin(-))骨髓细胞(BMC)的免疫反应以纠正 HA 小鼠出血性疾病中的作用。
将同种异体供体 Lin(-) BMC 与同种异体抗原致敏的 Treg 细胞共同移植到对乙酰氨基酚诱导急性肝损伤的 HA 小鼠体内。通过体外功能测定法测定血浆 FVIII 活性,并根据毛细血管凝血时间和断尾挑战评估出血表型的纠正情况。在体外和体内研究了致敏 Treg 细胞对 CD4(+) T 细胞的免疫抑制潜力。通过组织病理学评分分析致敏 Treg 细胞对归巢到肝脏的供体细胞的炎症反应的抑制作用。分别针对第三方供体检查致敏 Treg 细胞的同种异体特异性以及通过同种异体供体细胞的二次挑战检查免疫抑制的长期维持情况。还确定了供体 BMC 在肝脏中的植入和表型变化及其在 FVIII 合成和肝脏再生中的作用。
同种异体 Lin(-) BMC 与致敏 Treg 细胞共同移植导致全身免疫调节并抑制肝脏中的炎症反应,使同种异体细胞在肝脏中更好地植入。同种异体抗原引发即使在移植 1 年后仍导致同种异体特异性免疫抑制。供体来源的内皮细胞在 HA 小鼠中表达 FVIII,从而纠正出血表型。构成植入细胞主要部分的供体来源的肝细胞样细胞在急性损伤后支持肝脏再生。
通过在 HA 小鼠中移植同种异体 Lin(-) BMC 可以在再生肝脏中创建一个高效分泌 FVIII 的核心系统,在体外同种异体抗原引发的 Treg 细胞可以诱导对供体抗原的移植耐受。这种策略对于实现缺失蛋白的预防水平在遗传性肝脏疾病的治疗中可能是有益的。